Cargando…

Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial

BACKGROUND AND OBJECTIVE: Chronic mucus hypersecretion (CMH) is a clinical phenotype of COPD. This exploratory post hoc analysis assessed relationship between CMH status and treatment response in IMPACT. METHODS: Patients were randomized to once‐daily fluticasone furoate/umeclidinium/vilanterol (FF/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thompson, Philip J., Criner, Gerard J., Dransfield, Mark T., Halpin, David M. G., Han, MeiLan K., Lipson, David A., Maghzal, Ghassan J., Martinez, Fernando J., Midwinter, Dawn, Singh, Dave, Tombs, Lee, Wise, Robert A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804213/ https://www.ncbi.nlm.nih.gov/pubmed/35970518 http://dx.doi.org/10.1111/resp.14339

Ejemplares similares

Time‐Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial
por: Dransfield, Mark T., et al.
Publicado: (2022)

Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort
por: Stott-Miller, Marni, et al.
Publicado: (2020)

Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion
por: Tesfaigzi, Yohannes, et al.
Publicado: (2006)

The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial
por: Han, MeiLan K., et al.
Publicado: (2020)

Susceptibility to Chronic Mucus Hypersecretion, a Genome Wide Association Study
por: Dijkstra, Akkelies E., et al.
Publicado: (2014)

Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
por: Lipson, David A., et al.
Publicado: (2020)

Ciliary dyskinesia in severe asthma is not affected by chronic mucus hypersecretion
por: Kempeneers, Céline, et al.
Publicado: (2023)

Mucus Hypersecretion in Chronic Obstructive Pulmonary Disease and Its Treatment
por: Shah, Binay Kumar, et al.
Publicado: (2023)

Correction: Susceptibility to Chronic Mucus Hypersecretion, a Genome Wide Association Study
por: Dijkstra, Akkelies E., et al.
Publicado: (2015)

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
por: Tabberer, Maggie, et al.
Publicado: (2020)

Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease
por: Tian, Pan-wen, et al.
Publicado: (2015)

Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT
por: Dransfield, Mark T., et al.
Publicado: (2021)

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses
por: Halpin, David M.G., et al.
Publicado: (2018)

Discordant diagnostic criteria for pneumonia in COPD trials: a review
por: Wise, Robert A., et al.
Publicado: (2021)

Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial
por: Halpin, David M. G., et al.
Publicado: (2020)

Bronchial Thermoplasty for Severe Asthma with Mucus Hypersecretion
por: Nagano, Naoko, et al.
Publicado: (2019)

Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease
por: Yu, Suyun, et al.
Publicado: (2021)

MicroRNAs Associated with Chronic Mucus Hypersecretion in COPD Are Involved in Fibroblast–Epithelium Crosstalk
por: Tasena, Hataitip, et al.
Publicado: (2022)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
por: Day, Nicola C., et al.
Publicado: (2020)

Association of the CFTR gene with asthma and airway mucus hypersecretion
por: Crespo-Lessmann, Astrid, et al.
Publicado: (2021)

Discovery of a drug to treat airway mucus hypersecretion
por: Dickey, Burton F., et al.
Publicado: (2022)

Reply to Wang and Lai: The Role of Eosinophils during the Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
por: Han, MeiLan K., et al.
Publicado: (2021)

The effect of exacerbation history on outcomes in the IMPACT trial
por: Halpin, David M.G., et al.
Publicado: (2020)

PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases
por: Shen, Yongchun, et al.
Publicado: (2012)

Management of airway mucus hypersecretion in chronic airway inflammatory disease: Chinese expert consensus (English edition)
por: Shen, Yongchun, et al.
Publicado: (2018)

Therapeutic potential of Lianhua Qingke in airway mucus hypersecretion of acute exacerbation of chronic obstructive pulmonary disease
por: Hao, Yuanjie, et al.
Publicado: (2023)

Azithromycin Inhibits Mucus Hypersecretion from Airway Epithelial Cells
por: Shimizu, Takeshi, et al.
Publicado: (2012)

Cytokine Storm and Mucus Hypersecretion in COVID-19: Review of Mechanisms
por: Khan, Mohsin Ali, et al.
Publicado: (2021)

Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2020)

Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2021)

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial
por: Lazaar, Aili L., et al.
Publicado: (2020)

Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
por: Gabrio, Andrea, et al.
Publicado: (2022)

Daily use of guaifenesin (Mucinex) in a patient with chronic bronchitis and pathologic mucus hypersecretion: A case report
por: Storms, William W., et al.
Publicado: (2018)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
por: Ismaila, Afisi S, et al.
Publicado: (2019)

InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations
por: Singh, Dave, et al.
Publicado: (2021)

Mucus Hypersecretion and Ciliary Impairment in Conducting Airway Contribute to Alveolar Mucus Plugging in Idiopathic Pulmonary Fibrosis
por: Peng, Yang, et al.
Publicado: (2022)

Losartan reduces cigarette smoke-induced airway inflammation and mucus hypersecretion
por: Kim, Michael D., et al.
Publicado: (2021)

Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis
por: Han, MeiLan K., et al.
Publicado: (2021)

The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review
por: Calzetta, Luigino, et al.
Publicado: (2022)

Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β(2)-Agonist Therapy: An Integrated Post Hoc Analysis
por: Naya, Ian P., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d5m9pndnr227qvqle8mg0mns25